Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453175 | 0.97 | MIF (0.34) | MIFNR1H2 | |
| SCHEMBL7720760 | 0.97 | MIF (0.34) | MIFNR1H2 | |
| SCHEMBL5728730 | 0.97 | MIF (0.34) | MIFNR1H2 | |
| SCHEMBL247199 | 0.97 | MIF (0.34) | MIFNR1H2 | |
| SCHEMBL6125270 | 0.88 | MIF (0.34) | MIF | |
| SCHEMBL21097947 | 0.86 | MIF (0.33) | MIF | |
| SCHEMBL31070837 | 0.86 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL4015355 | 0.86 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL15887303 | 0.86 | MIF (0.33) | MIF | |
| SCHEMBL15887309 | 0.86 | MIF (0.33) | MIFNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812345-B2 | FUSED PYRIDINE-BENZAZAPINE, BENZOXEPIN, OR BENZOTHIEPIN DERIVATIVES; HYPOCHOLESTEROLEMIC AND HYPOLIPIDEMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-02 | — | — | US | disclosed |
| US-20040092573-A1 | HMG-CoA reductase inhibitors and method | ROBL JEFFREY A | 2004-05-13 | — | — | US | disclosed |
| US-20040024216-A1 | HMG-CoA reductase inhibitors and method | ROBL JEFFREY A (US) | 2004-02-05 | — | — | US | disclosed |
| US-6627636-B2 | Benzo(3,4)pyrido(3,2-a)cycloctenes and benzo(3,4)pyrido-(3,2-a)oxocins, -thiocins or azocines; anticholesterol, antilipemic agents; lowering LDL cholesterol; increasing HDl cholesterol; hypertriglyceridemia and atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-30 | — | — | US | disclosed |
| US-6620821-B2 | Tricyclic imine or amine oxime derivative; may be used in combination with one or more hypolipidemic agents or lipid-lowering agents or lipid agents or lipid modulating agents, and/or one or more other types of therapeutic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20020094977-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-18 | — | — | US | disclosed |
| US-20020061901-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | disclosed |
| US-20020028826-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-07 | — | — | US | disclosed |
| US-20020013334-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092573-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, APOB | MIF 3381/4885NR1H2 4/4885 |
| US-20020061901-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, NR1H2 | MIF 3483/4885NR1H2 3/4885 |
| US-20020028826-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, NR1H2 | MIF 3364/4885NR1H2 3/4885 |
| US-20020094977-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, NR1H2 | MIF 3252/4885NR1H2 3/4885 |
| US-20020013334-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, APOB | MIF 3622/4885NR1H2 6/4885 |
| US-20040024216-A1 | HMG-CoA reductase inhibitors and method | HMGCR, LDLR, NR1H2 | MIF 3264/4885NR1H2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.